<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="teaser">
 <p>Cytokine release syndrome grade 3 or higher was independently associated with increased risk of subsequent infection and in particular with bloodstream infection in patients with relapsed B-cell acute lymphoblastic leukemia treated with CD19 chimeric antigen receptor T-cell therapy.</p>
</abstract>
